2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2383

A Qualitative Study of Barriers and Facilitators to Arthritis Patients Use of Physical Activity Monitoring Tools
Abstract Number: 2507

A Quality Indicator for the Screening of Latent Tuberculosis Infection and the Result of Follow-up Interferon-Gamma-Release Assays in Patients with Rheumatic Disease Receiving Biologic Agents in a Japanese Hospital
Abstract Number: 3L

A Randomised Controlled Trial of the Clinical Effectiveness, Safety and Cost-Effectiveness of Adalimumab in Combination with Methotrexate for the Treatment of Juvenile Idiopathic Arthritis Associated Uveitis
Abstract Number: 2047

A Randomised Double-Blind Placebo-Controlled Trial of Vitamin D Supplementation in Juvenile-Onset Systemic Lupus Erythematosus: Effects on Microarchitecture Measured By HR-pQCT
Abstract Number: 3243

A Randomized Controlled Trial for a Physical Activity Intervention for RA Fatigue
Abstract Number: 2218

A Randomized Controlled Trial to Evaluate a Multimedia Patient Education Tool in Patients with Knee Osteoarthritis. Six-Month Results
Abstract Number: 898

A Randomized Double-Blind Study of Denosumab Compared with Zoledronic Acid in Postmenopausal Women with Osteoporosis Previously Treated with Oral Bisphosphonate
Abstract Number: 9L

A Randomized Double-Blind Trial of Abatacept and Glucocorticoids for the Treatment of Giant Cell Arteritis
Abstract Number: 2845

A Randomized, Clinical Trial to Assess the Relative Efficacy and Tolerability of Two Doses of Etoricoxib in Patients with Ankylosing Spondylitis
Abstract Number: 1647

A Randomized, Clinical Trial to Assess the Relative Efficacy and Tolerability of Two Doses of Etoricoxib in Patients with Rheumatoid Arthritis
Abstract Number: 3091

A Randomized, Controlled Trial of Pregabalin in Adolescent Patients (12-17 years) with Fibromyalgia
Abstract Number: 977

A Randomized, Double-Blind, Active- and Placebo-Controlled Phase 3 Study of Efficacy and Safety of Ixekizumab, Adalimumab, and Placebo Therapy in Patients Naïve to Biologic Disease Modifying Anti-Rheumatic Drugs with Active Psoriatic Arthritis
Abstract Number: 2056

A Randomized, Double-Blind, Phase III Study Comparing SB2, an Infliximab Biosimilar, to the Infliximab Reference Product (Remicade®) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy: 54-Week Results
Abstract Number: 3218

A Randomized, Double-Blind, Placebo-Controlled, 52-Week Study of the Efficacy and Safety of Belimumab Administered Subcutaneously Plus Standard Care to Patients with Systemic Lupus Erythematosus (SLE)
Abstract Number: 609

A Reduction in Serum Uric Acid Levels May be Related to Methotrexate Efficacy in Early Rheumatoid Arthritis: Data from a Canadian Arthritis Cohort

« Previous Page
1
…
5
6
7
8
9
…
218
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].